Robert A. Uger

1.5k total citations
38 papers, 737 citations indexed

About

Robert A. Uger is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Robert A. Uger has authored 38 papers receiving a total of 737 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Immunology, 9 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Robert A. Uger's work include Phagocytosis and Immune Regulation (17 papers), Immune Cell Function and Interaction (13 papers) and Immune cells in cancer (10 papers). Robert A. Uger is often cited by papers focused on Phagocytosis and Immune Regulation (17 papers), Immune Cell Function and Interaction (13 papers) and Immune cells in cancer (10 papers). Robert A. Uger collaborates with scholars based in United States, Canada and United Kingdom. Robert A. Uger's co-authors include Brian H. Barber, Steven M. Chan, Lisa D. Johnson, Christian P. Pallasch, Clemens‐Martin Wendtner, Michael Hallek, Penka S. Petrova, Reinhild Brinker, Mark Wong and Oleg E. Akilov and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Robert A. Uger

36 papers receiving 721 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert A. Uger United States	16	580	213	151	84	79	38	737
Mohammad Luqman United States	11	619 1.1×	150 0.7×	176 1.2×	82 1.0×	157 2.0×	26	864
Chun‐Jen J. Chen New Zealand	11	936 1.6×	283 1.3×	256 1.7×	25 0.3×	26 0.3×	15	1.1k
Carmeline O’Brien United States	8	533 0.9×	145 0.7×	128 0.8×	112 1.3×	141 1.8×	8	694
Sarah F. Brooks United States	6	210 0.4×	94 0.4×	238 1.6×	48 0.6×	17 0.2×	7	656
Magdalena Hagn Australia	11	560 1.0×	182 0.9×	94 0.6×	46 0.5×	20 0.3×	13	697
Dong‐Mei Zhao China	9	955 1.6×	316 1.5×	262 1.7×	47 0.6×	12 0.2×	20	1.2k
Gijs M.W. van Schijndel Netherlands	11	734 1.3×	168 0.8×	176 1.2×	58 0.7×	116 1.5×	15	885
So Matsui United States	6	1.1k 1.8×	451 2.1×	171 1.1×	16 0.2×	19 0.2×	8	1.2k
Gregory D. Rak United States	10	653 1.1×	129 0.6×	129 0.9×	15 0.2×	13 0.2×	12	953
Liang‐Ji Zhou United States	9	781 1.3×	205 1.0×	320 2.1×	131 1.6×	146 1.8×	10	1.1k

Countries citing papers authored by Robert A. Uger

Since Specialization

Citations

This map shows the geographic impact of Robert A. Uger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Uger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Uger more than expected).

Fields of papers citing papers by Robert A. Uger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Uger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Uger. The network helps show where Robert A. Uger may publish in the future.

Co-authorship network of co-authors of Robert A. Uger

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Uger. A scholar is included among the top collaborators of Robert A. Uger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Uger. Robert A. Uger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krishnamoorthy, Mithunah, Ruth Seelige, Christopher R. Brown, et al.. (2025). Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. Frontiers in Immunology. 16. 1518787–1518787.

Ni, Ying, Lisa D. Johnson, Peter G. Rose, et al.. (2023). Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition. npj Precision Oncology. 7(1). 69–69. 14 indexed citations

Kruglov, Oleg, Lisa D. Johnson, Kimberly R. Jordan, et al.. (2021). The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides. Cancer Immunology Immunotherapy. 71(4). 919–932. 8 indexed citations

Querfeld, Christiane, John A. Thompson, Matthew H. Taylor, et al.. (2021). Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. The Lancet Haematology. 8(11). e808–e817. 56 indexed citations

Rastogi, Namrata, Sarah M. Baker, Stephen Man, et al.. (2020). Use of an anti‐CD200‐blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology. 193(1). 155–159. 19 indexed citations

Diamanti, Paraskevi, et al.. (2017). Investigating the Efficacy of Anti-CD200 Immunotherapy in MRD Low and Risk B Cell Precursor ALL. Blood. 130. 3886–3886. 1 indexed citations

Querfeld, Christiane, John A. Thompson, Matthew H. Taylor, et al.. (2017). A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal. Blood. 130. 4076–4076. 15 indexed citations

Lin, Gloria H. Y., Vivian Lee, Karen Dodge, et al.. (2017). TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLoS ONE. 12(10). e0187262–e0187262. 51 indexed citations

Lin, Gloria H. Y., Hui Chen, Mark Wong, et al.. (2017). Abstract 2646: Intratumoral delivery of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, inhibits tumor growth and prolongs animal survival in a subcutaneous B cell lymphoma model. Cancer Research. 77(13_Supplement). 2646–2646. 1 indexed citations

10.

Thompson, John A., Oleg E. Akilov, Christiane Querfeld, et al.. (2017). A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.. Journal of Clinical Oncology. 35(15_suppl). TPS3101–TPS3101. 4 indexed citations

11.

Lin, Gloria H. Y., Vivian Lee, Karen Dodge, et al.. (2016). Abstract 2345: SIRPαFc, a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by both classically (M1) and alternatively (M2) activated macrophages. Cancer Research. 76(14_Supplement). 2345–2345. 1 indexed citations

12.

Uger, Robert A., Karen Dodge, Xinli Pang, & Penka S. Petrova. (2014). Abstract 5011: Cancer immunotherapy targeting CD47: Wild type SIRPαFc is the ideal CD47-blocking agent to minimize unwanted erythrocyte binding. Cancer Research. 74(19_Supplement). 5011–5011. 2 indexed citations

13.

Šimelyte, Egle, Gabriel Criado, David W. Essex, et al.. (2008). CD200‐FC, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen‐induced arthritis. Arthritis & Rheumatism. 58(4). 1038–1043. 44 indexed citations

14.

Pallasch, Christian P., et al.. (2008). Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leukemia Research. 33(3). 460–464. 72 indexed citations

15.

Pallasch, Christian P., Susanne E. Ulbrich, Reinhild Brinker, et al.. (2008). Disruption of T Cell Suppression in Chronic Lymphocytic Leukemia by CD200 Blockade.. Blood. 112(11). 2072–2072. 21 indexed citations

16.

Uger, Robert A., et al.. (2004). Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine. 23(13). 1559–1573. 56 indexed citations

17.

Astsaturov, Igor, Teresa M. Petrella, Emin Ümit Bağrıaçık, et al.. (2003). Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines.. PubMed. 9(12). 4347–55. 37 indexed citations

18.

Uger, Robert A., Steven M. Chan, & Brian H. Barber. (1999). Covalent Linkage to β2-Microglobulin Enhances the MHC Stability and Antigenicity of Suboptimal CTL Epitopes. The Journal of Immunology. 162(10). 6024–6028. 25 indexed citations

19.

Uger, Robert A. & Brian H. Barber. (1998). Creating CTL Targets with Epitope-Linked β2-Microglobulin Constructs. The Journal of Immunology. 160(4). 1598–1605. 44 indexed citations

20.

Uger, Robert A. & Brian H. Barber. (1997). Presentation of an influenza nucleoprotein epitope incorporated into the H-2Db signal sequence requires the transporter-associated with antigen presentation. The Journal of Immunology. 158(2). 685–692. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact